08.17.11
Syndax Pharmaceuticals Announces Issuance of EU Patent for Entinostat

Company focused on moving entinostat into phase 3 clinical trial

Read More
06.27.11
Syndax Pharmaceuticals Announces Entinostat Data from Two Lung Cancer Clinical Trials at Upcoming World Lung Conference
Read More
06.08.11
Syndax Pharmaceuticals Elects Arlene Morris to Board of Directors
Read More
06.02.11
Syndax Pharmaceuticals Announces Issuance of US Patent for Entinostat
Read More
03.31.11
Syndax Pharmaceuticals Announces Entinostat Data at 102nd Annual American Association for Cancer Research Meeting
Read More
03.01.11
Syndax Annouces Start of NCI Sponsored Phase 2 Study of Entinostat in Combination in Triple Negative Breast Cancer
SYNDAX ANNOUNCES START OF NCI SPONSORED PHASE 2 STUDY OF ENTINOSTAT IN COMBINATION IN TRIPLE NEGATIVE BREAST CANCER
Read More
02.10.11
Syndax Pharmaceuticals to Present at Bio CEO & Investor Conference
Read More
01.11.11
Syndax Announced Publication of Entinostat NSCLC Data in Cancer Research
Read More
01.04.11
Syndax Pharmaceuticals to Present at Biotech Showcase 2011
Read More
12.10.10
Syndax Pharmaceuticals' Entinostat in Combination Shows Activity in Breast Cancer
Read More
12.09.10
Syndax Pharmaceuticals' Entinostat Plus Erlotinib Improves Survival in Select NSCLC Patients
Syndax Pharmaceuticals' Entinostat Plus Erlotinib Improves Survival in Select NSCLC Patients Phase 2 data to be presented at 2010 Chicago Multidisciplinary Symposium in Thoracic Oncology
Read More
11.10.10
Syndax Pharmaceuticals to Present at Lazard Annual Healthcare Conference
Read More